Adaptive Deep Brain Stimulation Restores Music Conductor’s Career Amid Parkinson’s Battle
Ohio, USA – May 10, 2025
Rand Laycock, a 70-year-old Ohio symphony orchestra conductor, has reclaimed his ability to lead performances thanks to a breakthrough in Parkinson’s disease treatment: adaptive deep brain stimulation (aDBS). Diagnosed just before his 60th birthday, Laycock faced worsening tremors and dyskinesias—involuntary movements caused by long-term Parkinson’s medications—that threatened his 47-year career. A recent advancement in brain stimulation technology has nearly eliminated these symptoms, offering hope to others with the neurodegenerative disorder.
A Life-Altering Diagnosis
Laycock’s Parkinson’s journey began with a twitching thumb, leading to a diagnosis that he initially approached with optimism. “My doctor told me it wasn’t a death sentence, and there would be advancements over the next few years,” he told Cleveland Clinic. However, over the next 11 years, medications failed to control his progressing symptoms. Tremors in his right hand intensified, particularly under the stress of looming orchestra deadlines, and dyskinesias disrupted his precise conducting movements. “The tremor would really start to be pronounced if I had a deadline coming up,” Laycock said.
Discovering Deep Brain Stimulation
In 2024, Dr. Michal Gostkowski, a neurologist at Cleveland Clinic, introduced Laycock to deep brain stimulation (DBS), often described as a “pacemaker for the brain.” DBS involves implanting electrodes in specific brain areas, such as the subthalamic nucleus or globus pallidus interna, to deliver electrical currents that modulate abnormal neural signals causing Parkinson’s symptoms like tremors, rigidity, and bradykinesia (slowness of movement). In May 2024, Laycock underwent surgery to implant the device, with settings fine-tuned by programmer Erica Hennigs. The initial DBS therapy significantly reduced his tremors, allowing him to conduct with renewed confidence.
The Game-Changer: Adaptive DBS
While traditional DBS delivers constant stimulation, it doesn’t adapt to the fluctuating nature of Parkinson’s symptoms, which vary with medication levels, stress, or disease progression. Laycock’s symptoms, which fluctuated throughout the day, made him an ideal candidate for aDBS, a smarter, personalized version of the technology approved by the FDA in February 2025 for Parkinson’s treatment.
Adaptive DBS, developed by Medtronic and tested in trials led by Stanford neurologist Dr. Helen Bronte-Stewart, uses machine learning to monitor brain signals in real time, adjusting stimulation based on the patient’s needs. By tracking beta wave patterns—abnormal neural signals linked to Parkinson’s motor issues—aDBS delivers precise pulses to stabilize symptoms without over- or under-treating. “Like a cardiac pacemaker that responds to the heart’s rhythms, aDBS uses a person’s brain signals to control the electric pulses,” Bronte-Stewart explained.
��
Laycock began aDBS in March 2025, and the results were transformative. “My tremor is almost all gone, except if I experience extreme anxiety or stress,” he said. “My dyskinesia is pretty well under control, and my symptoms are minimal compared to the way they were.” Hennigs noted that aDBS reduced the risk of tremors disrupting performances, as it adjusts automatically if medication wears off mid-concert. “It sounded like it would make my life simpler—not having to worry about adjusting my device settings and medications as frequently,” Laycock added.
Impact and Broader Implications
The success of aDBS in Laycock’s case highlights its potential to revolutionize Parkinson’s treatment. A 2024 study funded by NIH’s BRAIN Initiative found aDBS reduced bothersome symptoms more effectively than conventional DBS, improving quality of life without significant side effects. Medtronic’s BrainSense Adaptive DBS, the first FDA-approved adaptive system, is now available to patients with compatible neurostimulators, marking the largest commercial launch of brain-computer interface technology.
Dr. Todd Herrington of Massachusetts General Hospital emphasized, “For patients who struggle with motor symptom fluctuations, dyskinesias, and other side effects with conventional DBS, aDBS may offer improved symptom control.” Gostkowski encourages patients to discuss DBS or aDBS with their doctors, noting its life-changing potential. Laycock himself urged others to consider it, despite the intimidating prospect of brain surgery: “It’s a life-changing procedure that allows you to become your own self again.”
A Return to Music and Family
Now in his 47th year of conducting, Laycock looks forward to continuing his passion for music and spending time with his wife, two children, and granddaughter. His story, celebrated in posts on X, underscores the hope aDBS offers for Parkinson’s patients. As one user, @yourpositivenws, wrote, “An Ohio music conductor with Parkinson’s is back leading his orchestra, thanks to a groundbreaking ‘pacemaker for the brain.’”
While aDBS is not a cure and challenges remain—such as the need for highly trained clinicians to set up devices—its ability to restore autonomy and quality of life marks a significant step forward in managing Parkinson’s. For Laycock, it has meant reclaiming the baton and the music he loves.
By [Your Name], with contributions from Fox News, Cleveland Clinic, Scientific American, and posts on X
Sources: